The effect of Achillea Millefolium on heavy menstrual bleeding

Clinical trial of Comparing the effect of Achillea Millefolium capsules and Mefenamic Acid on the amount and duration of menstrual bleeding in women affected by menorrhagia

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016073029126N1

Enrollment

Registered

2017-07-30

Start date

2016-02-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menorrhagia. excessive and frequent menturation with regular cycle

Interventions

Intervention 1: Intervention 1: In control group, Mefenamic acid capsule 500 mg every 8 hours and placebo capsules 500 mg per day every 12 hours, were prescribed from the first day to the end of b

Placebo

Treatment - Drugs

Intervention 1: In control group, Mefenamic acid capsule 500 mg every 8 hours and placebo capsules 500 mg per day every 12 hours, were prescribed from the first day to the end of bleeding up to se

Intervention 2: In Achillea Millefolium group, Mefenamic acid capsules, 500 mg every 8 hours and hydro alcoholic extract of Achillea Millefolium capsules, 500 mg per day every 12 hours,were prescrib

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:Affected by menorrhagia, Regular menstrual cycles,Body mass index between18.5- 29.5,Age between 18-45 years,No history of known systemic or pelvic inflammatory diseases, Not pregnant, No consumption of specific medications,No abnormal pap smear or ultrasonography, No history of sensitivity to medicinal plants. Exclusion criteria: Pregnancy during the study, Failure to adhere to prescribed treatment, sensitivity to the study medications, Unwilling to continue participation in the study,Occurrence a specific disease,Taking any herbal or chemical drug during the study,Occurrence of a specific event during the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Amount of bleeding. Timepoint: before treatment? First month during treatment, second month during treatment. Method of measurement: Higam Chart.;Duration of bleeding. Timepoint: before treatment? First month during treatment, second month during treatment. Method of measurement: Higam Chart.	—

Secondary

Measure	Time frame
Side effects of medication. Timepoint: 2 months after treatment. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKatayoun Vakilian

School of Nursing and Midwifery Of Arak

Dr.vakilian@arakmu.ac.ir+98 86 3417 3524

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026